Completed PHASE3 INTERVENTIONAL 2-arm NCT01008033

Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Sponsor: Dow Pharmaceutical Sciences

Updated 6 times since 2017 Last updated: Jun 20, 2012 Started: Nov 30, 2009 Primary completion: Nov 30, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Onychomycosis and is currently completed. Dow Pharmaceutical Sciences leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dow Pharmaceutical Sciences

Data source: Dow Pharmaceutical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Altamonte Springs, United States , Augusta, United States , Austin, United States , Barrie, Canada , Birmingham, United States , Boise, United States , Calgary, Canada , Cinncinati, United States , Clinton Township, United States and 44 more locations